Cargando…

Cutaneous and Noncutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy

Relationships between cutaneous adverse effects (CAEs) and noncutaneous adverse effects (NCAEs) of melanoma immunotherapy may help identify patterns tied to distinct immunologic pathways. The objective of this study was to determine the associations between CAEs and NCAEs among patients with stages...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeung, Howa, Supapannachart, Krittin J., Francois, Sandy, Adler, Colin H., Kudchadkar, Ragini R., Lawson, David H., Yushak, Melinda L., Shariff, Afreen I., Chen, Suephy C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661470/ https://www.ncbi.nlm.nih.gov/pubmed/38024559 http://dx.doi.org/10.1016/j.xjidi.2023.100232

Ejemplares similares

An Update in Management of Noncutaneous T-Cell Lymphomas
por: Hwang, Y. Y., et al.
Publicado: (2010)

Interactive Session for Residents and Medical Students on Dermatologic Care for Lesbian, Gay, Bisexual, Transgender, and Queer Patients
por: Barrett, Devon L., et al.
Publicado: (2021)

GIFT4-augmented B cells for melanoma immunotherapy
por: Deng, Jiusheng, et al.
Publicado: (2014)

Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition
por: Knochelmann, Hannah M., et al.
Publicado: (2022)

Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study
por: Kim, Hyo Song, et al.
Publicado: (2010)

Paraneoplastic cerebellar degeneration associated with noncutaneous Merkel cell carcinoma
por: Zhang, Cen, et al.
Publicado: (2014)

Dermoscopic Photographs Impact Confidence and Management of Remotely Triaged Skin Lesions
por: Rogers, Tova, et al.
Publicado: (2022)

A report of two deep-seated noncutaneous penile tumors: more than meets the eye
por: Thomas, Kerry, et al.
Publicado: (2017)

Outcome of external beam radiotherapy for treatment of noncutaneous tumors of the head in horses: 32 cases (1999‐2015)
por: Gillen, Alex, et al.
Publicado: (2020)

Splenic injury following endoscopic drainage of a large pancreatic pseudocyst: a case report
por: Supapannachart, Krittin J., et al.
Publicado: (2021)

Outpatient dermatology clinic half days with more women, racial minority, and younger patients generate fewer work relative value units
por: Supapannachart, Krittin J., et al.
Publicado: (2022)

Anthropometry in the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Cutaneous melanoma and the immunotherapy revolution (Review)
por: Leonardi, Giulia C., et al.
Publicado: (2020)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Patient Factors Associated with Interest in Teledermatology: Cross-sectional Survey
por: Ghani, Maham, et al.
Publicado: (2021)

Deeper Sections: Its Frequency and Diagnostic Utility in Histopathology of Noncutaneous Small Biopsy Specimen in a Tertiary Hospital in Nepal
por: Lama, Gopal, et al.
Publicado: (2021)

Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review)
por: Volovat, Simona Ruxandra, et al.
Publicado: (2021)

Treating Acne in Transgender Persons Receiving Testosterone: A Practical Guide
por: Radi, Rakan, et al.
Publicado: (2022)

Critically appraised topic on adverse food reactions of companion animals (6): prevalence of noncutaneous manifestations of adverse food reactions in dogs and cats
por: Mueller, Ralf S., et al.
Publicado: (2018)

Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
por: Sadozai, Hassan, et al.
Publicado: (2017)

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Cutaneous Events Associated with Immunotherapy of Melanoma: A Review
por: Burzi, Lorenza, et al.
Publicado: (2021)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
por: Nikolaou, Vasiliki, et al.
Publicado: (2023)

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023)

Angiofibroma stimulation in a transgender person receiving gender-affirming testosterone
por: Bubley, Jeffrey A., et al.
Publicado: (2020)

Testosterone deficiency in men receiving immunotherapy for malignant melanoma
por: Peters, Madeline, et al.
Publicado: (2021)

Balancing Inflammation: The Link between Th17 and Regulatory T Cells
por: Diller, Maggie L., et al.
Publicado: (2016)

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
por: Sullivan, Ryan J., et al.
Publicado: (2018)

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
por: Russo, Irene, et al.
Publicado: (2018)

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
por: Aris, Mariana, et al.
Publicado: (2017)

Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review
por: Naik, Piyu Parth
Publicado: (2021)

Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma
por: Liu, Qian, et al.
Publicado: (2021)

Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter
por: Thornton, Jessica, et al.
Publicado: (2022)

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma
por: Premi, Sanjay, et al.
Publicado: (2022)

Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2021)

Cutaneous Melanoma versus Vulvovaginal Melanoma—Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy
por: Lorenz, Anna, et al.
Publicado: (2022)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016)

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2022)

Reporting Melanoma: A Nationwide Surveillance of State Cancer Registries
por: Raji, Kehinde O., et al.
Publicado: (2015)

FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma
por: Wu, Shaobo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rct8ukdug4nvvqsc3u15rk2904